Moneta Group Investment Advisors’s Arbutus Biopharma ABUS Stock Holding History

Moneta Group Investment Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Hold	26,000	–	–	﹤0.01%	855
2026 Q1	$117K	Hold	26,000	–	–	﹤0.01%	781
2025 Q4	$125K	Hold	26,000	–	–	﹤0.01%	787
2025 Q3	$118K	Hold	26,000	–	–	﹤0.01%	774
2025 Q2	$80.3K	Hold	26,000	–	–	﹤0.01%	694
2025 Q1	$90.7K	Hold	26,000	–	–	﹤0.01%	652
2024 Q4	$85K	Buy	26,000 +1,000	+4%	+$3.68K	﹤0.01%	650
2024 Q3	$96.3K	Hold	25,000	–	–	﹤0.01%	635
2024 Q2	$77.3K	Hold	25,000	–	–	﹤0.01%	595
2024 Q1	$64.5K	Hold	25,000	–	–	﹤0.01%	595
2023 Q4	$62.5K	Buy	25,000 +2,000	+9%	+$3.92K	﹤0.01%	549
2023 Q3	$46.7K	Buy	23,000 +4,000	+21%	+$8.39K	﹤0.01%	514
2023 Q2	$43.7K	Buy	19,000 +4,000	+27%	+$10.4K	﹤0.01%	533
2023 Q1	$45.5K	Buy	15,000 +4,937	+49%	+$13.9K	﹤0.01%	525
2022 Q4	$30.3K	Sell	10,063 -3,026	-23%	-$7.24K	﹤0.01%	451
2022 Q3	$25K	Buy	13,089 +3,864	+42%	+$9.1K	﹤0.01%	424
2022 Q2	$25K	Buy	+9,225	New	+$23.6K	﹤0.01%	462

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Moneta Group Investment Advisors's ABUS Position: Q2 2026 in Review

Moneta Group Investment Advisors held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 26,000 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #855.

Moneta Group Investment Advisors first reported a position in ABUS in Q2 2022 and has held it in 17 quarters since. The position peaked at $125K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Moneta Group Investment Advisors held 26,000 shares of Arbutus Biopharma worth $125K as of Q2 2026.
Moneta Group Investment Advisors left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Moneta Group Investment Advisors's portfolio in Q2 2026, its #855 holding.
Moneta Group Investment Advisors first reported a position in Arbutus Biopharma in Q2 2022 and has held it in 17 quarters since.
Moneta Group Investment Advisors's Arbutus Biopharma position peaked at $125K in Q4 2025.
176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Moneta Group Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.